MaxCyte to acquire Akron BioProducts for $151.8 million
MaxCyte (MXCT) agreed to acquire Akron BioProducts for $151.8M, including cash, stock, and deferred payments. Akron is projected to generate $28M revenue and $7-8M EBITDA in 2026. The deal is expected to close by year-end 2026 and nearly double MaxCyte's revenue. MaxCyte secured a $75M credit facility for the acquisition.
How this was made
The 30-second read
Why it matters
The acquisition adds ~$28M of revenue and $7‑8M EBITDA in 2026, aiming to cut combined cash burn to under $10M in 2027.
Market read
A material M&A deal for a mid‑cap biotech equipment company, likely to move MXCT stock on announcement.
What to watch
Potential regulatory review of the acquisition and the impact of deferred payments on future cash flow.
Background
MaxCyte is a cell‑therapy technology company; Akron BioProducts supplies GMP‑grade reagents for cell therapy manufacturing.
Ticker impact
MaxCyte announced a $151.8M acquisition of Akron BioProducts, adding cash and stock consideration.
upside pressure as investors price in revenue expansion and improved cash flow profile.
Acquisition size is material for a mid‑cap, cash component and strategic fit are clear, and no financing condition is required.
Market effects
Strengthens the cell‑therapy manufacturing supply chain, may benefit peers in biotech equipment space.
Positive for US biotech sector, limited broader market effect.
Modest, primarily a US‑focused biotech M&A event.
Counterpoint
Deal dilution and integration risk could weigh on the stock if execution falters.
Key entities
- CompanyMaxCyte, Inc.
Acquirer, US‑listed biotech equipment firm.
- CompanyAkron BioProducts LLC
Target, private supplier of cell‑therapy reagents.
